We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

102 hedge funds and large institutions have $729M invested in Dianthus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

369% more call options, than puts

Call options by funds: $2.68M | Put options by funds: $572K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

6% more capital invested

Capital invested by funds: $685M → $729M (+$43.1M)

4.22% more ownership

Funds ownership: 117.38% → 121.6% (+4.2%)

4% more funds holding

Funds holding: 98 → 102 (+4)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

28% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 40

Holders
102
Holders Change
+4
Holders Change %
+4.08%
% of All Funds
1.34%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
18
Increased
29
Reduced
40
Closed
14
Calls
$2.68M
Puts
$572K
Net Calls
+$2.11M
Net Calls Change
+$3.03M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$28.1M
2
BBA
Baker Bros. Advisors
New York
+$14.8M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.33M
4
Goldman Sachs
Goldman Sachs
New York
+$5.46M
5
Millennium Management
Millennium Management
New York
+$3.66M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$14M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$13.7M
3
B
Braidwell
Connecticut
-$6.81M
4
GPP
Great Point Partners
Connecticut
-$4.99M
5
BlackRock
BlackRock
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
26
Alphabet Inc
California
$3.89M – – –
Millennium Management
27
Millennium Management
New York
$3.64M +$3.66M +195,357 New
Adage Capital Partners
28
Adage Capital Partners
Massachusetts
$3.45M -$75K -4,000 -2%
SSA
29
Schonfeld Strategic Advisors
New York
$3.21M +$3.23M +172,039 New
Bank of America
30
Bank of America
North Carolina
$3.08M +$1.35M +71,838 +77%
Charles Schwab
31
Charles Schwab
California
$3.06M -$71.1K -3,789 -2%
Northern Trust
32
Northern Trust
Illinois
$2.99M -$1.41M -75,218 -32%
Morgan Stanley
33
Morgan Stanley
New York
$2.57M +$1.1M +58,681 +74%
Ensign Peak Advisors
34
Ensign Peak Advisors
Utah
$2.5M +$2.52M +134,416 New
UBS Group
35
UBS Group
Switzerland
$2.45M +$1.58M +84,052 +177%
RPAM
36
Rhenman & Partners Asset Management
Sweden
$2.36M – – –
Hudson Bay Capital Management
37
Hudson Bay Capital Management
Connecticut
$2.15M +$758K +40,425 +54%
SCM
38
Silverarc Capital Management
Massachusetts
$1.78M -$1.77M -94,528 -50%
ECM
39
ExodusPoint Capital Management
New York
$1.4M +$1.41M +75,079 New
Wellington Management Group
40
Wellington Management Group
Massachusetts
$1.39M +$119K +6,369 +9%
MAP
41
Moody Aldrich Partners
Massachusetts
$1.36M -$20.7K -1,106 -1%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.24M -$130K -6,926 -9%
Barclays
43
Barclays
United Kingdom
$1.21M +$632K +33,680 +108%
Ameriprise
44
Ameriprise
Minnesota
$1.05M +$1.06M +56,261 New
American Century Companies
45
American Century Companies
Missouri
$1.01M +$119K +6,323 +13%
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$923K +$904K +48,173 +3,547%
N
47
Nuveen
North Carolina
$889K -$313K -16,688 -26%
CSS
48
Cubist Systematic Strategies
Connecticut
$808K +$405K +21,563 +99%
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
$691K – – –
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$587K -$66.5K -3,544 -10%
1
2
3 4 5

DNTH Hedge Fund Activity: Q2 2025 in Review

102 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2025, worth a combined $729M — up 6.3% from $685M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DNTH positions and 14 closed out — a net gain of 4 holders — while 29 added to existing stakes and 40 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $28.1M. The largest seller was VR Adviser, cutting an estimated $14M.

  • 102 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2025, up from 98 in Q1 2025.
  • Funds reported $729M of Dianthus Therapeutics stock for Q2 2025, up 6.3% quarter-over-quarter.
  • 18 funds opened new Dianthus Therapeutics positions in Q2 2025 and 14 closed out, a net change of +4 holders.
  • The largest Dianthus Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $28.1M added.
  • The largest Dianthus Therapeutics seller in Q2 2025 was VR Adviser, an estimated $14M sold.

Based on aggregated 13F filings for Q2 2025.